Pharmaceutical Business Review
Return to: PBR Home

News

View news from other Pharmaceutical sectors:
31-45 of 50849 results
Researchers show aspirin added to cancer drug improves effectiveness
Adding aspirin to some existing cancer drugs could increase their effectiveness against a group of tumours resistant to treatment, new research has shown.
Drug Research > Drug Discovery & Development > News
Blue Oak, PsychoGenics enter into drug discovery partnership
Blue Oak Pharmaceuticals and PGI Drug Discovery (PsychoGenics) have entered into a partnership to discover and optimize novel treatments for brain disorders and psychiatric conditions.
Drug Research > Drug Discovery & Development > News
AbbVie’s risankizumab meets all primary endpoints in fourth phase 3 psoriasis trial
By PBR Staff Writer
AbbVie’s psoriasis drug risankizumab (150 mg) has met all the primary endpoints in the two phases of a fourth pivotal phase 3 clinical trial in patients with moderate to severe plaque psoriasis.
Contract Research & Services > Clinical Trials > News
Astellas Pharma acquires Mitobridge for $225m
Astellas Pharma has exercised its exclusive option right to acquire Mitobridge under the amended terms of the October 2013 partnership agreement governing their research and development (R&D) collaboration focused on discovering and developing novel drugs that target mitochondrial function.
Drug Research > Drug Discovery & Development > News
I-Mab Biopharma partners with MorphoSys on cancer investigational medicine
I-Mab Biopharma and MorphoSys have entered into an exclusive regional licensing agreement to develop and commercialize MOR202 in China, Taiwan, Hong Kong and Macao.
Drug Research > Drug Discovery & Development > News
Amgen’s Repatha approved by FDA for heart attack and stroke prevention
By PBR Staff Writer
Amgen’s cholesterol drug Repatha (evolocumab) has been approved by the US Food and Drug Administration (FDA) to prevent heart attacks, strokes and coronary revascularizations in adults having cardiovascular disease.
News
resTORbio raises $40m from biotech and institutional investors
resTORbio, a clinical-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of aging-related diseases, has raised $40m in a Series B financing round.
Drug Research > Drug Discovery & Development > News
NIH and partners commence HIV vaccine efficacy trial
The National Institutes of Health (NIH) and partners have started a clinical trial to evaluate whether an experimental HIV vaccine regimen is safe and effective in prevention of HIV infection.
Contract Research & Services > Clinical Trials > News
Indivior's Sublocade secures FDA approval to treat opioid use disorder
By PBR Staff Writer
Indivior’s Sublocade (buprenorphine extended- release) injection has been approved by the US Food and Drug Administration (FDA) for the treatment of moderate to severe opioid use disorder (OUD).
Regulatory Affairs > News
Revance Therapeutics plans phase 3 program for RT002 injectable to treat cervical dystonia
Revance Therapeutics has completed its End-of-Phase 2 meeting with the US Food and Drug Administration (FDA) and has received scientific advice from the Europe Medicines Agency (EMA) regarding DaxibotulinumtoxinA for Injection (RT002) for the treatment of cervical dystonia.
Contract Research & Services > Clinical Trials > News
Melinta Therapeutics to buy The Medicines Company's infectious disease business
Melinta Therapeutics has agreed to acquire the infectious disease business from The Medicines Company.
Production & Manufacturing > Manufacturing > News
Novartis and Amgen’s erenumab succeeds in phase 3 episodic migraine trial
By PBR Staff Writer
Novartis and Amgen’s human monoclonal antibody erenumab has succeeded in a phase 3 study by demonstrating significant and sustained efficacy in the prevention of episodic migraine.
Contract Research & Services > Clinical Trials > News
Viking’s VK5211 meets primary endpoint in phase 2 hip fracture trial
By PBR Staff Writer
Viking Therapeutics’ hip fracture treatment VK5211 has met primary endpoint in a 12-week phase 2 clinical trial.
Contract Research & Services > Clinical Trials > News
Titan to grant European marketing rights of Probuphine to Molteni
Titan Pharmaceuticals has agreed to grant L. Molteni & C. dei F.lli Alitti Società di Esercizio (Molteni) an exclusive license to commercialize Probuphine in the European Union, Switzerland, Norway, Iceland, Liechtenstein, Bosnia, Serbia, Montenegro, Macedonia and Albania.
Production & Manufacturing > Manufacturing > News
Takeda starts phase 1 trial of Zika virus vaccine candidate
By PBR Staff Writer
Japan's Takeda Pharmaceutical has started a phase 1 clinical trial of its purified, inactivated, alum-adjuvanted, whole Zika virus vaccine candidate, TAK-426.
Contract Research & Services > Clinical Trials > News
31-45 of 50849 results